{"id":"https://openalex.org/W2520164030","doi":"https://doi.org/10.1093/jiplp/jpw078","title":"R&D crisis in drug discovery for neglected diseases: scope for an open source approach to pharmaceutical research","display_name":"R&D crisis in drug discovery for neglected diseases: scope for an open source approach to pharmaceutical research","alternate_titles":[],"publication_year":2016,"publication_date":"2016-08-01","ids":{"openalex":"https://openalex.org/W2520164030","doi":"https://doi.org/10.1093/jiplp/jpw078","mag":"2520164030"},"language":"en","primary_location":{"id":"doi:10.1093/jiplp/jpw078","doi":"https://doi.org/10.1093/jiplp/jpw078","is_oa":false,"landing_page_url":"https://doi.org/10.1093/jiplp/jpw078","pdf_url":null,"source":{"id":"https://openalex.org/S82472405","display_name":"Journal of Intellectual Property Law & Practice","issn_l":"1747-1532","issn":["1747-1532","1747-1540"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["abdc-b","anvur-scientific","jufo-1","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Intellectual Property Law &amp; Practice","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2520164030"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037379525","display_name":"Narendran Thiruthy","orcid":"https://orcid.org/0000-0002-7043-8388","observed_orcids":["https://orcid.org/0000-0002-7043-8388"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Narendran Thiruthy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5037379525"],"corresponding_institution_ids":[],"apc_list":{"value":4291,"currency":"EUR","value_usd":4850},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":92},"biblio":{"volume":"11","issue":"8","first_page":"599","last_page":"611"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9179999828338623,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.9179999828338623,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11675","display_name":"Open Source Software Innovations","score":0.02370000071823597,"subfield":{"id":"https://openalex.org/subfields/1706","display_name":"Computer Science Applications"},"field":{"id":"https://openalex.org/fields/17","display_name":"Computer Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.013399999588727951,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-discovery","display_name":"drug discovery","score":0.9789999723434448},{"id":"https://openalex.org/keywords/neglected-diseases","display_name":"neglected diseases","score":0.9879999756813049},{"id":"https://openalex.org/keywords/pharmaceutical-industry","display_name":"pharmaceutical industry","score":0.5659999847412109},{"id":"https://openalex.org/keywords/drug-development-costs","display_name":"drug development costs","score":0.7390000224113464},{"id":"https://openalex.org/keywords/drug-approval-rates","display_name":"drug approval rates","score":0.7110000252723694},{"id":"https://openalex.org/keywords/new-chemical-entities","display_name":"new chemical entities","score":0.7329999804496765},{"id":"https://openalex.org/keywords/research-productivity","display_name":"research productivity","score":0.4699999988079071}],"concepts":[{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.6987208724021912},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.5849649906158447},{"id":"https://openalex.org/C2778012447","wikidata":"https://www.wikidata.org/wiki/Q1034415","display_name":"Scope (computer science)","level":2,"score":0.5733840465545654},{"id":"https://openalex.org/C109747225","wikidata":"https://www.wikidata.org/wiki/Q815758","display_name":"Scarcity","level":2,"score":0.5589785575866699},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.5492467880249023},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4615016579627991},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4377613067626953},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.41724711656570435},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.35053473711013794},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.23928651213645935},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.20949795842170715},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.1959126889705658},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.14179787039756775},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C175444787","wikidata":"https://www.wikidata.org/wiki/Q39072","display_name":"Microeconomics","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1093/jiplp/jpw078","doi":"https://doi.org/10.1093/jiplp/jpw078","is_oa":false,"landing_page_url":"https://doi.org/10.1093/jiplp/jpw078","pdf_url":null,"source":{"id":"https://openalex.org/S82472405","display_name":"Journal of Intellectual Property Law & Practice","issn_l":"1747-1532","issn":["1747-1532","1747-1540"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["abdc-b","anvur-scientific","jufo-1","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Intellectual Property Law &amp; Practice","raw_type":"journal-article"},{"id":"pmh:oai:open-archive.highwire.org:jiplap:11/8/599","doi":null,"is_oa":false,"landing_page_url":"http://jiplp.oxfordjournals.org/cgi/content/short/11/8/599","pdf_url":null,"source":{"id":"https://openalex.org/S4406923041","display_name":"HighWire Press Open Archive","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"TEXT"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.5683000087738037,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4403431496","https://openalex.org/W2412640784","https://openalex.org/W1977052981","https://openalex.org/W1550938699","https://openalex.org/W7095645638","https://openalex.org/W2016375513","https://openalex.org/W4388166432","https://openalex.org/W2768094704","https://openalex.org/W2014414702","https://openalex.org/W2167692381"],"abstract_inverted_index":{"Pharmaceutical":[0],"R&D":[1,189,241],"begins":[2],"with":[3],"the":[4,26,38,44,78,102,120,133,160,173,177,181,188,198,219,247,250,270,277],"work":[5],"needed":[6],"to":[7,25,46,101,125,136,143,172,205,246,257],"understand":[8],"a":[9,20,31,48,57,72,138,185,224,267],"particular":[10],"disease":[11,39,58],"and":[12,41,55,74,119,129,213,272,275],"its":[13],"conditions.":[14],"Once":[15],"this":[16,96,236],"process":[17,114],"has":[18,43,71,152,183,242,253,265,286],"reached":[19],"critical":[21],"point,":[22],"research":[23,70,264],"shifts":[24],"discovery":[27,202,263],"or":[28,36,59],"synthesis":[29],"of":[30,68,131,159,187,200,210,216,238,279],"molecule":[32],"that":[33,93,154,164,234,249],"will":[34,98,107],"influence":[35],"palliate":[37],"condition":[40,60],"thus":[42],"potential":[45,81,161],"be":[47,62,99,108,144],"medicine.":[49],"This":[50],"involves":[51],"finding":[52],"out":[53],"how":[54],"where":[56,105],"can":[61],"successfully":[63],"attacked.":[64],"The":[65,112,149,191],"development":[66],"part":[67],"pharmaceutical":[69,150,240],"pre-clinical":[73,79],"clinical":[75,103],"stage.":[76],"In":[77],"stage":[80,97,104],"drug":[82,162,201,228,262],"candidates":[83,92,163],"are":[84,165],"studied":[85],"for":[86],"their":[87],"effect":[88],"on":[89,110],"animals.":[90],"Drug":[91],"qualify":[94],"at":[95],"taken":[100],"they":[106],"tested":[109],"humans.":[111],"entire":[113],"is":[115,141,232],"highly":[116],"complex,":[117,245],"expensive":[118],"success":[121],"rates":[122],"low.":[123],"According":[124],"PhRMA":[126],"(Pharmaceutical":[127],"Research":[128],"Manufacturers":[130],"America)":[132],"average":[134],"cost":[135],"develop":[137],"new":[139],"medicine":[140],"estimated":[142],"around":[145],"US$2.6":[146],"billion.":[147],"1":[148],"industry":[151,182],"asserted":[153],"only":[155],"one":[156],"in":[157,227,261],"5,000":[158],"put":[166],"through":[167],"these":[168],"stages":[169],"make":[170],"it":[171],"market.":[174],"2":[175],"Over":[176],"past":[178],"few":[179],"years":[180],"advanced":[184],"theory":[186],"crisis.":[190],"2011":[192],"Oliver":[193],"Wyman":[194],"report":[195],"interestingly":[196],"divided":[197],"history":[199],"from":[203],"1996":[204],"2004":[206],"into":[207],"an":[208,214],"era":[209,215],"abundance":[211],"(1996\u20132004)":[212],"scarcity":[217],"(2005-10),":[218],"latter":[220],"being":[221],"characterized":[222],"by":[223],"40%":[225],"fall":[226],"approvals.":[229],"3":[230],"It":[231],"argued":[233],"over":[235],"period":[237],"time,":[239],"grown":[243],"more":[244],"point":[248],"productivity":[251],"challenge":[252],"become":[254],"particularly":[255],"difficult":[256],"overcome.":[258],"4":[259],"Productivity":[260],"experienced":[266],"downturn":[268],"since":[269],"1990s,":[271],"between":[273],"1998":[274],"2008":[276],"number":[278],"\u2018new":[280],"molecular":[281],"entities\u2019":[282],"approved":[283],"per":[284],"year":[285],"declined.":[287],"5":[288]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2520164030","counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-09-23T00:00:00"}
